Peter M. R. Gaze Acquires 15,000 Shares of Marlowe plc (LON:MRL) Stock
by Michael Walen · The Markets DailyMarlowe plc (LON:MRL – Get Free Report) insider Peter M. R. Gaze purchased 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of GBX 309 ($4.13) per share, with a total value of £46,350 ($61,998.39).
Marlowe Trading Up 2.4 %
Shares of LON MRL opened at GBX 328.83 ($4.40) on Wednesday. The company has a quick ratio of 0.80, a current ratio of 1.24 and a debt-to-equity ratio of 58.99. The stock’s 50 day moving average price is GBX 436.14 and its two-hundred day moving average price is GBX 482.13. Marlowe plc has a 52-week low of GBX 220 ($2.94) and a 52-week high of GBX 620 ($8.29). The stock has a market capitalization of £289.37 million, a P/E ratio of -2,344.64 and a beta of 0.44.
Analyst Upgrades and Downgrades
MRL has been the topic of a number of analyst reports. Berenberg Bank reaffirmed a “buy” rating and set a GBX 710 ($9.50) target price on shares of Marlowe in a research report on Wednesday, August 21st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a GBX 690 ($9.23) target price on shares of Marlowe in a research report on Thursday, August 1st.
Read Our Latest Report on Marlowe
Marlowe Company Profile
Marlowe plc provides compliance services and software in the United Kingdom. The company operates in two segments, Governance, Risk and Compliance; and Testing, and Inspection and Certification. It offers health and safety consultancy, risk and audit assessments, environmental, contractor management, and training services; and health and safety support services.
Recommended Stories
- Five stocks we like better than Marlowe
- What is a Bond Market Holiday? How to Invest and Trade
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Stock Average Calculator
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What Investors Need to Know About Upcoming IPOs
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?